Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7810441 | 0.73 | MAPK13 (0.54) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL27842253 | 0.73 | MAPK14 (0.54) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL667134 | 0.72 | MAPK14 (0.59) | MAPK14MAPK13MAPK11RAF1ERBB2 | |
| SCHEMBL3629669 | 0.72 | MAPK14 (0.48) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL7813599 | 0.70 | MAPK13 (0.48) | AAK1MAPK14MAPK13RAF1 | |
| SCHEMBL3628470 | 0.69 | MAPK14 (0.58) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL6049963 | 0.69 | MAPK14 (0.43) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL7811988 | 0.68 | MAPK14 (0.49) | AAK1MAPK14MAPK13MAPK11RAF1 | |
| SCHEMBL6049531 | 0.67 | CDC7 (0.33) | MAPK14CCNCCDK8 | |
| SCHEMBL3631505 | 0.66 | MAPK14 (0.53) | MAPK14MAPK13MAPK11RAF1MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4403482-B2 | — | — | 2010-01-27 | — | — | JP | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | claimed |
| JP-2001526223-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |